Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Oncology
Vincenza Conteduca, Daniel Wetterskog, Elena Castro, Emanuela Scarpi, Nuria Romero-Laorden, Giorgia Gurioli, Anuradha Jayaram, Cristian Lolli, Giuseppe Schepisi, Anna Wingate, Chiara Casadei, Rebeca Lozano, Nicole Brighi, Isabel M. Aragon, Mercedes Marin-Aguilera, Enrique Gonzalez-Billalabeitia, Begona Mellado, David Olmos, Gerhardt Attard, Ugo De Giorgi
Summary: The relevance of plasma AR in the overall management of CRPC patients receiving different docetaxel doses is currently unknown.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Haozhe Zhang, Yi Zhou, Zengzhen Xing, Rajiv Kumar Sah, Junqi Hu, Hailiang Hu
Summary: This review discusses the close relationship between the evolution of prostate cancer and androgen levels and the status of the androgen receptor. It also explores how alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jorgensen, Tuula Kallunki, Martin A. Roder, Klaus Brasso, Jose M. A. Moreira
Summary: Itraconazole can re-sensitize docetaxel-resistant prostate and breast cancer cells by binding to ABC transporter protein ABCB1, inhibiting the transport of docetaxel.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Margherita Corti, Stefano Lorenzetti, Alessandro Ubaldi, Romano Zilli, Daniele Marcoccia
Summary: The role of endocrine disruptors in the human prostate gland is overlooked, but they can influence the homeostasis and diseases of the prostate, including prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Tae Jin Kim, Young Hwa Lee, Kyo Chul Koo
Summary: The androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa), and treatment for hormone-sensitive prostate cancer (HSPC) relies heavily on androgen deprivation therapy (ADT). Despite most patients progressing to castration-resistant prostate cancer (CRPC), studies suggest that manipulating alternative molecular pathways can help improve current treatments and develop novel therapies for CRPC management.
Article
Pharmacology & Pharmacy
Yingying Zhang, Hongxia Duan, Heming Zhao, Lingling Qi, Yanhong Liu, Zheao Zhang, Chao Liu, Liqing Chen, Mingji Jin, Youyan Guan, Zhonggao Gao, Wei Huang
Summary: In this study, a nanosystem was designed for the treatment of prostate cancer, carrying both docetaxel and androgen receptor siRNA. The results demonstrated that the nanosystem exhibited prolonged blood circulation, selective targeting, and enhanced antitumor effects, holding great potential for efficient treatment of castration-resistant prostate cancer by combining chemotherapy and siRNA silencing of androgen-related signaling pathways.
Article
Andrology
Georg Schaefer, Nikola Bednarova, Axel Heidenreich, Helmut Klocker, Isabel Heidegger
Summary: The study found that KDM5D is significantly overexpressed in patients who respond to chemotherapy, indicating that KDM5D may be a promising new biomarker for predicting treatment response in mCRPC.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2021)
Article
Oncology
Natalia Jimenez, Oscar Reig, Mercedes Marin-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Albert Font, Alejo Rodriguez-Vida, Miguel Angel Climent, Sara Cros, Isabel Chirivella, Montserrat Domenech, Mariona Figols, Enrique Gonzalez-Billalabeitia, Daniel Jimenez Peralta, Leonardo Rodriguez-Carunchio, Samuel Garcia-Esteve, Marta Garcia de Herreros, Maria J. Ribal, Aleix Prat, Begona Mellado
Summary: In this study, transcriptomic analysis was used to investigate the predictive value of gene expression in the clinical outcomes of mHSPC patients treated with ADT+DX. The results showed that high expression of AR and ESR signatures and low expression of TSG are associated with better prognosis. These molecular alterations may serve as potential biomarkers for personalized treatment selection.
Article
Oncology
Xiaolei Shi, Abderrahman Day, Hannah E. Bergom, Sydney Tape, Sylvan C. Baca, Zoi E. Sychev, Gabrianne Larson, Asha Bozicevich, Justin M. Drake, Nicholas Zorko, Jinhua Wang, Charles J. Ryan, Emmanuel S. Antonarakis, Justin Hwang
Summary: The study identifies B7-H3 as an immune checkpoint overexpressed in prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide-resistant mCRPC cells show increased expression of B7-H3, and it is associated with resistance signaling pathways. The gene network of B7-H3 is strongly correlated with androgen receptor (AR) and its co-factors, suggesting potential therapeutic targets for mCRPC.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Zemin Hou, Shengsong Huang, Zhenfei Li
Summary: Androgens are crucial in the development of prostate cancer, and targeting steroidogenesis and the androgen receptor has been effective in delaying disease progression. New generation androgen receptor pathway inhibitors like abiraterone and enzalutamide continue to emphasize the role of the androgen-AR axis, even in cases of resistance. The importance of this axis in managing the disease after resistance to current treatments, particularly in neuroendocrine prostate cancer, remains uncertain.
Article
Medicine, Research & Experimental
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Summary: The study identified BCT as a potent inhibitor targeting both AR-FL and AR-V7 activities in CRPC, effectively suppressing tumor growth and metastasis. Mechanistically, BCT disrupts the interaction of HSP90 with AR-FL/AR-V7, leading to their degradation and showing promising therapeutic potential against CRPC.
Article
Oncology
Cheng Qian, Dan Li, Yu Chen
Summary: The ETS family of proteins plays critical roles in prostate cancer, and gene fusion and overexpression of certain members have been linked to the development of this cancer. This review provides an overview of the discovery, classification, and therapeutic targeting of ETS family members in prostate cancer.
Review
Biochemistry & Molecular Biology
Navid Sobhani, Praveen Kumar Neeli, Alberto D'Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi
Summary: Metastatic prostate cancer is the most common cancer in males with a poor prognosis, and many patients develop the AR-V7 variant. AR-V7 acts as a transcription factor in the nucleus, repressing crucial tumor suppressor genes. Anti-AR-V7 drugs show promise for this subset of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Charles J. Ryan, Thian Kheoh, Jinhui Li, Arturo Molina, Peter De Porre, Joan Carles, Eleni Efstathiou, Philip W. Kantoff, Peter F. A. Mulders, Fred Saad, Kim N. Chi
CLINICAL GENITOURINARY CANCER
(2018)
Article
Oncology
Masaaki Yamamoto, Caining Jin, Tsuyoshi Hata, Yota Yasumizu, Yan Zhang, Deli Hong, Takahiro Maeda, Masaaki Miyo, Masayuki Hiraki, Yozo Suzuki, Kunihiko Hinohara, Hasan Rajabi, Donald Kufe
Article
Oncology
Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Kufe
MOLECULAR CANCER THERAPEUTICS
(2019)
Article
Oncology
Tsuyoshi Hata, Hasan Rajabi, Hidekazu Takahashi, Yota Yasumizu, Wei Li, Caining Jin, Mark D. Long, Qiang Hu, Song Liu, Atsushi Fushimi, Nami Yamashita, Ling Kui, Deli Hong, Masaaki Yamamoto, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Mehmet K. Samur, Donald Kufe
Article
Oncology
Yamin Qian, Xin Wu, Yuhki Yokoyama, Daisuke Okuzaki, Mai Taguchi, Haruka Hirose, Jiaqi Wang, Tsuyoshi Hata, Akira Inoue, Masayuki Hiraki, Masahisa Ohtsuka, Hidekazu Takahashi, Naotsugu Haraguchi, Tsunekazu Mizushima, Shinji Tanaka, Masaki Mori, Hirofumi Yamamoto
Article
Surgery
Masaru Murata, Masayuki Hiraki, Akira Hagiwara, Hirokazu Sawami, Rei Suzuki, Hiroki Fukunaga, Nobuo Tanaka, Akira Inoue, Hidekazu Takahashi, Shunji Morita
WORLD JOURNAL OF SURGERY
(2020)
Article
Oncology
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Shingo Noura, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh
Summary: Lessons learned from this study indicate that panitumumab monotherapy is effective and feasible for frail or elderly patients with RAS wild-type unresectable colorectal cancer, especially for left-sided tumors. It could be considered as an additional therapeutic option for those who are not suitable for intensive chemotherapy.
Article
Surgery
Yukari Kihara, Yutaka Takeda, Yoshiaki Ohmura, Yoshiteru Katsura, Go Shinke, Ryo Ikeshima, Shinsuke Katsuyama, Kenji Kawai, Masayuki Hiraki, Keijiro Sugimura, Toru Masuzawa, Atsushi Takeno, Taishi Hata, Kohei Murata
Summary: This study reported four cases of non-absorbable polymer clip migration after laparoscopic surgery, which can lead to complications in the bile duct and gallbladder. The risk of NAPC migration should be considered in patients undergoing laparoscopic surgery.
SURGICAL CASE REPORTS
(2021)
Article
Surgery
Masayuki Hiraki, Rei Suzuki, Nobuo Tanaka, Hiroki Fukunaga, Yoshinori Kinoshita, Hayato Kimura, Shusaku Tsutsui, Masaru Murata, Shunji Morita
Summary: This case report presents a rare case of community-acquired fulminant pseudomembranous colitis caused by ribotype 027 C. difficile after H. pylori eradication therapy in a 68-year-old woman. In Japan, this strain is reported to be uncommon, making this case notable.
SURGICAL CASE REPORTS
(2021)
Article
Surgery
Taishi Hata, Kenji Kawai, Atsushi Naito, Yoshinori Kagawa, Tomohiro Kitahara, Masayuki Hiraki, Go Shinke, Shinsuke Katsuyama, Yoshiteru Katsura, Yoshiaki Ohmura, Toru Masuzawa, Atsushi Takeno, Yutaka Takeda, Takeshi Kato, Kohei Murata
Summary: This study compared the short- and long-term outcomes of single-incision laparoscopic surgery (SILS) and conventional laparoscopic surgery (CLS) for right-sided colon cancer. The results showed that SILS had advantages in terms of operating time and bleeding volume, and the long-term outcomes were comparable to CLS. Therefore, SILS could be considered as a treatment option for right-sided colon cancer.
EUROPEAN SURGICAL RESEARCH
(2023)
Article
Surgery
Masaki Sakaue, Keijiro Sugimura, Toru Masuzawa, Atsushi Takeno, Shinnsuke Katsuyama, Go Shinnke, Ryo Ikeshima, Kenji Kawai, Masayuki Hiraki, Yoshiteru Katsura, Yoshiaki Ohmura, Taishi Hata, Yutaka Takeda, Kohei Murata
Summary: This case demonstrates the possibility of conversion surgery after systemic chemotherapy for stage IV advanced gastric cancer with liver metastasis.
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS
(2022)
Article
Oncology
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Hironaga Satake, Shingo Noura, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Toshimasa Tsujinaka, Taroh Satoh
Summary: This study aimed to investigate the efficacy of panitumumab in patients with RAS wild-type colorectal cancer. The results showed that panitumumab demonstrated favorable overall survival in frail or elderly patients without prior exposure to chemotherapy, with a more significant effect observed in patients with left-sided tumors.
Article
Chemistry, Medicinal
Naoto Tsujimura, Takayuki Ogino, Masayuki Hiraki, Taisei Kai, Hiroyuki Yamamoto, Haruka Hirose, Yuhki Yokoyama, Yuki Sekido, Tsuyoshi Hata, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Tsunekazu Mizushima, Yuichiro Doki, Hidetoshi Eguchi, Hirofumi Yamamoto
Summary: This study identified miR-497a-5p as a microRNA that can activate the TGF-beta/Smad signal pathway and demonstrated its therapeutic efficacy in a mouse model of inflammatory bowel disease.
Article
Orthopedics
Hiroshi Kusafuka, Masayuki Hiraki, Kenji Kawai, Ryo Ikeshima, Taishi Hata, Kiminori Yanagisawa, Mitsuru Kinoshita, Shinsuke Katsuyama, Go Shinke, Yoshiaki Ohmura, Keijiro Sugimura, Toru Masuzawa, Yutaka Takeda, Kohei Murata
Summary: A persistent descending mesocolon is a congenital fixation anomaly caused by defective membrane fusion. Anatomically, the left colonic artery is often shortened, and the colonic mesentery adheres firmly to the small intestine mesentery. An understanding of this condition is important during left-sided colorectal cancer surgery, and blood flow assessment using indocyanine green fluorescence can be useful for evaluating bowel ischemia.
ASIAN JOURNAL OF ENDOSCOPIC SURGERY
(2023)
Article
Oncology
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Hironaga Satake, Shingo Noura, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Toshimasa Tsujinaka, Taroh Satoh
Summary: This study presents a survival analysis of panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer. The results showed favorable overall survival in these patients, particularly in those with left-sided tumors.